Allele and genotype frequency of CYP2C9 in Tamilnadu population

European Journal of Clinical Pharmacology

Volumn 59, Issue 8-9, 2003, Pages 707-709

  Adithan, C ^a   Gerard, N ^b   Vasu, S ^a   Balakrishnan, R ^a   Shashindran, C H ^a   Krishnamoorthy, R ^b  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

CYP2C9; Polymorphism; Tamilnadu

Indexed keywords

CYTOCHROME P450 2C9;

ADULT; ARTICLE; CAUCASIAN; CHINESE; CYP2C9 GENE; ENZYME POLYMORPHISM; ETHNIC DIFFERENCE; FEMALE; GENE; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN CELL; INDIA; LEUKOCYTE; MALE; NORMAL HUMAN; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INDIA; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 0345528204     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0666-3     Document Type: Article

References (24)

1. Raucy JL, Allen SW (2001) Recent advances in P450 research. Pharmacogenomics J 1:178-186
2. Miners JO, Birkett DJ (1998) Cytochrome P450 2C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525-538
3. Rogers JF, Nafziger AN, Bertino JS Jr (2002) Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 113:746-750
4. Daly AK, King BP (2003) Pharmacogenetics of oral anticoagulants. Pharmacogenetics 13:247-252
5. Ingelman-Sundberg M, Daly AK, Newbert DW (2003) Homepage of the human cytochrome P450 (CYP) allele nomenclature committee. URL:http://www.imm.ki.se/ cypalleles/cyp2c9.htm. (ref type: electronic citation, accessed on 10/ 07/2003)
6. Lee CR, Goldstein JA, Pieper JA (2002) Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12:251-263
7. Aithal GP, Day CP, Kesteven PJ, Daly AK (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717-719
8. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR (1994) Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4:39-42
9. Miners J (2002) CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response. Pharmacogenetics 12:91-92
10. van der WJ, Steijns LS, van Weelden MJ, de Haan K (2001) The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 11:287-291
11. Verstuyft C, Morin S, Robert A, Loriot MA, Beaune P, Jaillon P, Becquemont L (2001) Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. Pharmacogenetics 11:735-737
12. Gaedigk A, Casley WL, Tyndale RF, Sellers EM, Jurima-Romet M, Leeder JS (2001) Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol 79:841-847
13. Wang SL, Huang J, Lai MD, Tsai JJ (1995) Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 5:37-42
14. Krishnamurthi B (2003) The Dravidian languages. Cambridge University Press, Cambridge
15. Desai A (2001) The Original Indians: an enquiry. Media house, New Delhi
16. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341-349
17. Crespi CL, Miller VP (1997) The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 7:203-210
18. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R (2002) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72:702-710
19. Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT (1999) Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 9:71-80
20. Ninomiya H, Mamiya K, Matsuo S, Ieiri I, Higuchi S, Tashiro N (2000) Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. Ther Drug Monit 22:230-232
21. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J (2002) Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E-and Z-doxepin in healthy volunteers. Pharmacogenetics 12:571-580
22. Kirchheiner J, Meineke I, Freytag G, Meisel C, Roots I, Brockmoller J (2002) Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin Pharmacol Ther 72:62-75
23. Kirchheiner J, Brockmoller J, Meineke I, Bauer S, Rohde W, Meisel C, Roots I (2002) Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 71:286-296
24. Aithal GP, Day CP, Leathart JB, Daly AK (2000) Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 10:511-518